NICE backs Sobi's Tryngolza for rare disease FCS
Patients in England and Wales with familial chylomicronaemia syndrome will soon have a new treatment option, as NICE backs Sobi's Tryngolza.
Newsletters and Deep Dive digital magazine
Patients in England and Wales with familial chylomicronaemia syndrome will soon have a new treatment option, as NICE backs Sobi's Tryngolza.
CMS has finalised a new drug pricing policy for Medicare that has drawn sharp criticism from the pharma industry.
Two Indian nationals are facing charges relating to the sale of counterfeit versions of Novo's diabetes treatment Ozempic to distributors in the US.
A new study suggests long-read 'nanopore' sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.
The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.
Editor's Picks
Newsletters and Deep Dive
digital magazine